Kezar Life Sciences, Inc. Update: The Company Has Been Acquired

If you have been following Kezar Life Sciences (KZR), there is a major update. Following the struggles we discussed regarding their experimental drug, the company has officially been bought out. Here is the breakdown of what this means for you.

1. What happened?

Aurinia Pharmaceuticals Inc. acquired Kezar Life Sciences through a merger agreement. The deal closed on May 11, 2026. Kezar is no longer an independent, publicly traded company; it is now a wholly owned subsidiary of Aurinia.

2. What does this mean for shareholders?

If you held KZR stock when the merger closed, your shares were canceled. In exchange, you are entitled to:

• Cash: You receive $6.955 per share in cash, minus any applicable taxes.
• A "CVR": You also received one "Contingent Value Right" (CVR) per share. This is a non-transferable right to potential future cash payments if Aurinia hits specific clinical or regulatory goals with Kezar’s remaining assets.

Kezar has delisted from the Nasdaq. You can no longer buy or sell KZR stock, as your ownership interest has been converted into this merger payout.

3. Why did this happen?

Kezar focused on developing therapies for immune-mediated diseases. Their lead drug, zetomipzomib, hit a major roadblock when Kezar paused clinical testing due to safety concerns. For a biotech firm, losing its lead drug often creates a cash crisis. Selling to Aurinia provided a structured exit, allowing shareholders to capture immediate cash rather than risking the company running out of money or undergoing a painful restructuring.

4. What happens to the leadership and employees?

Kezar’s Board of Directors and executive officers have resigned, and Aurinia has installed its own management team. The company didn't provide much detail about the specific future of the remaining staff, but the focus has shifted entirely to Aurinia’s integration strategy.

5. Why does this matter?

• For Investors: The high-risk chapter of KZR is closed. Your investment has been liquidated at the agreed-upon price. The CVR is the only remaining "wildcard" that could pay out more money if Aurinia successfully navigates future hurdles.
• For the Industry: This deal shows a common exit strategy for biotech firms facing clinical trial failures. When a company’s main pipeline stalls, it often becomes a target for larger firms that have the cash to salvage the intellectual property.

6. What should you do?

Your brokerage firm should process the cash payment automatically. Check your account statements to confirm the cash has been deposited and that your CVRs are properly credited. Since CVRs are non-transferable and tied to future milestones, keep any documentation from your broker regarding their terms and expiration. These rights represent your only potential for future gains from this investment.

Final Thought: Since you can no longer trade KZR, your primary task is to monitor your brokerage account to ensure the cash payout has arrived and to keep an eye on any official communications from Aurinia regarding the CVR milestones. If you have questions about the tax implications of this cash payout, it is a good idea to consult with a tax professional.

Disclaimer: I am an AI, not a financial advisor. Stock market investments carry risk. Always do your own research or talk to a professional before making investment decisions.